EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling

Prostate

Volumn 69, Issue 5, 2009, Pages 528-537

  DeHaan, Alyse M ^a   Wolters, Natalie M ^a   Keller, Evan T ^a   Ignatoski, Kathleen M Woods ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Bone metastasis; Cell signaling; Epidermal growth factor receptor; Prostate cancer; TGF , EGF

Indexed keywords

EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR ALPHA; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TNFSF11 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE REMODELING; CANCER GROWTH; CANCER STAGING; CELL COMMUNICATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; ADENOCARCINOMA; BIOLOGICAL MODEL; BONE TUMOR; DISEASE COURSE; DRUG EFFECT; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOCARCINOMA; BONE NEOPLASMS; BONE REMODELING; CELL LINE, TUMOR; DISEASE PROGRESSION; EPIDERMAL GROWTH FACTOR; HUMANS; LIGANDS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, BIOLOGICAL; NEOPLASM STAGING; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RANK LIGAND; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 61949330322     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20903     Document Type: Article

References (41)

1. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 1987;56:881-914.
2. Seth D, Shaw K, Jazayeri J, Leedman PJ. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Br J Cancer 1999;80:657-669. (Pubitemid 29209826)
3. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995;1:545-550.
4. Liu XH, Wiley HS, Meikle AW. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J Clin Endocrinol Metab 1993;77:1472-1478. (Pubitemid 24000898)
5. Myers RB, Kudlow JE, Grizzle WE. Expression of transforming growth factor-alpha, epidermal growth factor, and epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. Mod Pathol 1993;6:733-737. (Pubitemid 2014278)
6. Ching KZ, Ramsey E, Pettigrew N, D'Cunha R, Jason M, Dodd JG. Expression of mRNA for epidermal growth factor, transforming growth factor-alpha, and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 1993;126:151-158. (Pubitemid 24004520)
7. Torring N, Hansen FD, Sorensen BS, Orntoft TF, Nexo E. Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition. Prostate 2005;64:1-8. (Pubitemid 40734733)
8. Logothetis CJ, Lin S-H. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-28. (Pubitemid 40052322)
9. Gusterson B. Identification and, interpretation of epidermal growth factor and c-erbB-2 overexpression. Eur J Cancer 1992;28:263-267.
10. Shah RB, Ghosh D, Elder JT. Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: Correlation with androgen independence. Prostate 2006;66:1437-1444. (Pubitemid 44350369)
11. Mimeault M, Pommery N, Henichart JP. New advances on prostate carcinogenesis and therapies: Involvement of EGF-EGFR transduction system. Growth Factors 2003;21:1-14. (Pubitemid 36790449)
12. Mimeault M, Johansson S, Venkatraman G, Moore E, Henichart J, Depreux P, Lin M, Batra S. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 2007;6:967-978. (Pubitemid 46554566)
13. Mimeault M, Venkatraman G, Johansson S, Moore E, Henichart J, Depreux P, Lin M, Batra S. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 2007;120:160-169.
14. Normanno N, Maiello M, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action? J Cell Physiol 2003;194:13-19.
15. Normanno N, Bianco C, De Luca A, Maiello M, Salomon D. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. Endocr Relat Cancer 2003;10:1-21. (Pubitemid 36457237)
16. Festuccia C, Angelucci A, Gravina G, Biordi L, Millimaggi D, Muzi P, Vicentini C, Bologna M. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 2005;93:964-975.
17. Festuccia C, Gravina GL, Angelucci A, Millimaggi D, Muzi P, Vincentini C, Bologna M. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer 2005;115:630-640. (Pubitemid 40656723)
18. Angelucci A, Gravina G, Rucci N, Millimaggi D, Festuccia C, Muzi P, Teti A, Vicentini C, Bologna M. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 2006;13:197-210.
19. Legrier M, Oudard S, Judde J, Guyader C, de Pinieux G, Boye K, de Cremoux P, Dutrillaux B, Poupon M. Potentiation of antitumour activity of docetaxel by combination with trastuzumabin a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 2007;96:269-276. (Pubitemid 46160632)
20. Formento P, Hannoun-Levi J, Gerard F, Mazeau C, Fischel J, Etienne-Grimaldi M, Gugenheim J, Milano G. Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. Eur J Cancer 2005;41:1467-1473. (Pubitemid 40826472)
21. Kim S, Uehara H, Karashima T, Shepherd D, Killion J, Fidler I. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003;9:1200-1210. (Pubitemid 36323730)
22. Wong A, Soong R, Seah S, Lim S, Chuah K, Nga M, Chin T, Soo R. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008;3:400-404.
23. Wilding G, Soulie P, Trump D, Das-Gupta A, small E. Results from a pilot phase 1 trial of Gefitinib combined with docetaxel and Estramustine in patients with hormone refractory prostate cancer. Cancer 2006;106:1917-1924.
24. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000;6:1038-1045. (Pubitemid 30159365)
25. Oliver B, Sha'afi R, JJ H. Transforming growth factor-alpha and epidermal growth factor activate mitogen-activated protein kinase and its substrates in intestinal epithelial cells. Proc Soc Exp Biol Med 1995;210:162-170.
26. Marte B, Graus-Porta D, Jeschke M, Fabbro D, Hynes N, Taverna D. NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells. Oncogene 1995;10:167-175.
27. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241. (Pubitemid 27456390)
28. Woods Ignatoski KM, Livant DL, Markwart S, Grewal NK, Ethier SP. The role of PI3′kinase and its downstream signals in erbB-2-mediated transformation. Mol Cancer Res 2003;1:551-560. (Pubitemid 36577050)
29. Udagawa N, Takahashi N, Jimi E,Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie M, Martin T, Suda T. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: Receptor activator of NF-kappa B ligand. Bone 1999;25:517-523. (Pubitemid 29469457)
30. Itonaga I, Sabokbar A, Murray D, Athanasou N. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. Ann Rheum Dis 2000;59:26-31. (Pubitemid 30303893)
31. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004;64:9209-9216. (Pubitemid 39665537)
32. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65:7554-7560. (Pubitemid 41297224)
33. Hall C, Kang S, MacDougald O, Keller E. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 2006;97:661-672.
34. Hall C, Keller E. The role of Wnts in bone metastases. Cancer Metastasis Rev 2006;25:551-558. (Pubitemid 46074998)
35. Woods Ignatoski K, Escara-Wilke J, Dai J-L, Lui A, Dougall W, Daignault S, Yao Z, Zhang J, Day M, Sargent E, Keller E. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 2008;68:820-829.
36. Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 2004;4:308-318. (Pubitemid 39504359)
37. Mundy G. Preclinical models of bone metastases. Semin Oncol 2001;28:2-8. (Pubitemid 32844922)
38. Mundy G. Mechanisms of bone metastasis. Cancer 1997;80:1546-1556. (Pubitemid 27444026)
39. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 1994;57:406-412. (Pubitemid 24168617)
40. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-2581. (Pubitemid 24173741)
41. Woods Ignatoski KM, LaPointe AJ, Radany EH, Ethier SP. ErbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology 1999;140:3615-3622. (Pubitemid 30645416)